JPRN-UMIN000018166招募中未知
Efficacy and safety in SGLT2 inhibitor for diabetes complicated by non-alcoholic fatty liver disease. - SGLT2 inhibitor for diabetes complicated by NAFLD.
Toranomon Hospital, Department of Hepatology0 个研究点目标入组 15 人开始时间: 2015年7月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 64years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Contraindication for SGLT2 inhibitor. Ineligible patients by judgement of family doctor.
研究者
相似试验
已完成
不适用
Efficacy and safety in SGLT2 inhibitor for non-diabetes complicated by non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.JPRN-UMIN000031041Kobe university school of medicine, Diabetes and Endocrinoplogy30
已完成
不适用
The efficacy and safety of SGLT2 inhibitor for non alcholic fatty liver disease in Japanese patients with type 2 diabetesJPRN-UMIN000016306Tokyo Medical and Dental University50
招募中
不适用
Efficacy and safety of SGLT2 inhibitor in patients with diabetic kidneyDiabetic nephropathyJPRN-UMIN000031454ihon University40
招募中
不适用
Efficacy and Safety of SGLT2 inhibitors in patients with type 1 diabete.type 1 diabetesJPRN-UMIN000044317Hokkaido University Hospital200
招募中
不适用
Effects of a SGLT2 Inhibitor in type 2 Diabetes Mellitustype 2 Diabetes MellitusJPRN-UMIN000017461ephrology, endocrinology and vascular medicine at Tohoku University Hospital60